PGR and breast carcinoma: As endocrine therapy only plays a role in ER and PR-positive breast cancer patients (Burstein et al., 2016; Spring et al., 2016; Franzoi et al., 2021), the current rapid drug resistance of breast cancer to chemotherapy and endocrine therapy also greatly reduces the benefits of breast cancer patients (Nakao et al., 2018; Garcia-Martinez et al., 2021; Lloyd et al., 2022).